Aeglea Biotherapeutics, Inc. (AGLE) EPS Estimated At $-0.55; Advent Claymore Convertible Securities & Income Fund Has 0.59 Sentiment

February 15, 2018 - By reb123z

Analysts expect Aeglea Biotherapeutics, Inc. (NASDAQ:AGLE) to report $-0.55 EPS on March, 22.They anticipate $0.14 EPS change or 34.15% from last quarter’s $-0.41 EPS. After having $-0.48 EPS previously, Aeglea Biotherapeutics, Inc.’s analysts see 14.58% EPS growth. The stock increased 2.28% or $0.14 during the last trading session, reaching $6.29. About 7,273 shares traded. Aeglea Biotherapeutics, Inc. (NASDAQ:AGLE) has declined 11.96% since February 15, 2017 and is downtrending. It has underperformed by 28.66% the S&P500.

The stock increased 0.52% or $0.08 during the last trading session, reaching $15.34. About 1,391 shares traded. Advent Claymore Convertible Securities and Income Fund (AVK) has risen 17.65% since February 15, 2017 and is uptrending. It has outperformed by 0.95% the S&P500.

Windsor Capital Management Llc holds 2.14% of its portfolio in Advent Claymore Convertible Securities and Income Fund for 262,190 shares. Saba Capital Management L.P. owns 1.07 million shares or 1.76% of their US portfolio. Moreover, Arete Wealth Advisors Llc has 1.1% invested in the company for 169,850 shares. The Illinois-based Koshinski Asset Management Inc. has invested 0.71% in the stock. Rivernorth Capital Management Llc, a Illinois-based fund reported 490,383 shares.

Aeglea Biotherapeutics, Inc., a biotechnology company, develops enzyme therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer. The company has market cap of $104.69 million. The Company’s human enzymes are designed to degrade specific amino acids in the blood. It currently has negative earnings. The company's lead product candidate, AEB1102 is human Arginase I, engineered to reduce arginine levels to treat patients with Arginase I deficiency and patients with arginine-dependent solid tumors and hematological malignancies.

Among 4 analysts covering Aeglea BioTherapeutics (NASDAQ:AGLE), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aeglea BioTherapeutics had 4 analyst reports since May 2, 2016 according to SRatingsIntel. The rating was initiated by Wells Fargo on Monday, May 2 with “Outperform”. On Monday, May 2 the stock rating was initiated by UBS with “Buy”. BMO Capital Markets initiated the stock with “Outperform” rating in Monday, May 2 report. The firm earned “Buy” rating on Monday, May 9 by Needham.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


>